Kura to Present Phase 1 ccRCC Data on Darlifarnib Plus Cabozantinib at IKCS Europe
Kura Oncology will present updated Phase 1 FIT-001 data on darlifarnib plus cabozantinib in advanced clear cell renal carcinoma patients at IKCS Europe 2026. These results build on 2025 findings by showing encouraging clinical activity and a manageable safety profile, supporting darlifarnib’s ability to overcome resistance to VEGFR TKI therapy.
1. Presentation Details
Kura Oncology will present updated data from its ongoing FIT-001 Phase 1 trial evaluating darlifarnib (KO-2806) plus cabozantinib in advanced clear cell renal carcinoma patients at the International Kidney Cancer Symposium Europe 2026 on April 17, session 7 (3:30–4:30 p.m. CEST).
2. Updated FIT-001 Results
The combination of darlifarnib and cabozantinib demonstrated encouraging clinical activity and a manageable safety profile in patients with advanced clear cell renal carcinoma, building on preliminary findings reported in 2025.
3. Darlifarnib Mechanism of Action
Darlifarnib is a next-generation farnesyl transferase inhibitor designed to inhibit RHEB farnesylation and suppress mTORC1 signaling, potentially enhancing the activity of VEGFR-targeted therapies such as cabozantinib.
4. Virtual Investor Call
A webcast and conference call is scheduled for April 17 at 7:30 a.m. PT / 10:30 a.m. ET / 4:30 p.m. CEST, featuring Kura management and a clinical investigator, with live webcast and replay available on the company’s investor website.